MODIFICATION
65 -- Pandemic Preparedness (Tamiflu)
- Notice Date
- 6/26/2018
- Notice Type
- Modification/Amendment
- NAICS
- 424210
— Drugs and Druggists' Sundries Merchant Wholesalers
- Contracting Office
- Department of Justice, Federal Bureau of Investigation, Procurement Section, 935 Pennsylvania Avenue, N.W., Washington, District of Columbia, 20535, United States
- ZIP Code
- 20535
- Solicitation Number
- RFI-HCPU-18-317
- Archive Date
- 10/1/2018
- Point of Contact
- Larry D. Gillman, Phone: 7039851593
- E-Mail Address
-
ldgillman@fbi.gov
(ldgillman@fbi.gov)
- Small Business Set-Aside
- N/A
- Description
- REQUEST FOR INFORMATION Pandemic Preparedness (Tamiflu) RFI-HCPU-18-317 1.0Description 1.1The Federal Bureau of Investigation (FBI) in support of the Health Care Program Unit (HCPU) is seeking information on capabilities of interested contractor for continued supply of United States Food and Drug Administration (FDA) approved anti-viral medication Tamiflu for its Pandemic Flu Preparedness Program. The medicine shall have been demonstrated by the United States Centers for Disease Control (CDC) to be effective in treating Influenza A, H1N1 Influenza and H5N1 Avian Influenza. 1.2THIS IS A REQUEST FOR INFORMATION (RFI) ONLY. This RFI is issued solely for the information and planning purposes - it does not constitute a Request for Proposal (RFP)/Request for Quote (RFQ) or a promise to issue an RFP/RFQ in the future. This request for information does not commit the Government to contract for any supply or service whatsoever. Further, the FBI is not at this time seeking proposals/quotes and will not accept unsolicited proposals/quotes. Respondees are advised that the U.S. Government will not pay for any information or administrative costs incurred in response to this RFI; all costs associated with responding to this RFI will be solely at the interested party's expense. Not responding to this RFI does not preclude participation in any future RFP/RFQ, if any is issued. If a solicitation is released, it will be synopsized on the Federal Business Opportunities (FedBizOpps) website. It is the responsibility of the potential offerors to monitor these sites for additional information pertaining to this requirement. 1.3The Government anticipates a period of performance of one (1) base year of 12 months and four (4) option years, each 12 months in length. 1.4The contract type is anticipated to be a Firm Fixed-Price Blanket Purchase Agreement (BPA). 1.5Capability Statements shall be submitted in Microsoft Word for Office 2013 compatible format are due no later than July 6, 2018, 3:00PM EST. Responses shall be limited to 3 pages and submitted via email only to Larry D. Gillman, Contracting Officer ldgillman@fbi.gov. Proprietary information, if any, should be minimized and MUST BE CLEARLY MARKED. To aid the Government, please segregate proprietary information. Additional submission of documents such as paragraph 5.0 shall not count towards the 3 page limitation. Submissions of excessive documents or capability statements exceed the 3 page limitation will be disregarded at the discretion of the Government. 2.0Background The FBI has identified a continuous need for pandemic Tamiflu to support is Pandemic Preparedness stockpile. The FBI's need is for approximately 3,300 does of Tamiflu each year and in order to meet the Pandemic Strategic National Stockpile (SNS) requirements the stockpile must be rotated on continuous use and expiring medications. The product is oseltamivir (Tamiflu) 75mg capsules in containers of 10 caps per bottle. The product is required annually and must have a single lot number and single expiration date that is no less than eight (8) years from the date of delivery.   3.0Requested Information Respondees will submit capability statement addressing all requirements. All responses shall be single page in Microsoft Word 2013 format utilizing Times New Roman font 11. Responses should indicate this is a submission in response to RFI-HCPU-18-317. 4.0Requirements 4.1Product is oseltamivir (Tamiflu) 75mg capsules x 10 caps per bottle. 4.2Ability to deliver all orders no later than fourth (4th) quarter Government fiscal year, July through September timeframe each year, to include the present fiscal year. 4.3Product must have a single lot number and a single expiration date no less than twelve months from the date of delivery. 4.4Product shall contain medicine sufficient for one course five (5) days treatment or ten (10) days prophylaxis. 4.5Product packaging shall be in accordance with the United States Health and Human Services (HHS) Strategic National Stockpile (SNS) packaging. 4.6Product labeling shall be in accordance with HHS SNS labeling requirements. 4.7Product shall be labeled FOR DEPARTMENT OF DEFENSE STOCKPILE USE ONLY. 4.8The expiration date of the Tamiflu shall be no less than eight (8) years from the date of delivery and shall have an NDC number of 0004-0800-07. 4.9Delivery shall be FOB-Destination and delivery locations will be designated for each order however will be one of the following four locations; Washington D.C.; Fredericksburg, VA; Dallas, TX; or Los Angeles, CA. 5.0Additional Submission Respondees will include the following information in their capabilities package: (1)Company name, Company address, Company business size, Point-of-Contact (POC) with name, phone number, fax number, and e-mail address. (2)Company profile to include number of employees, annual revenue history, office location(s), CAGE Code, DUNS number, and a statement regarding current small/large business status. (3)Qualifications, if applicable, as a Small, Small Disadvantaged, Small Disadvantaged Veteran Owned Small Business, Woman-Owned, 8(a), Hub Zone or Service Disabled Veteran-Owned Small Business Concern. (4)Company's GSA contract number (if applicable) (5)System for Award Management (SAM) registered NAICS codes (6)Quality assurance plans that meet or exceed the United States Food and Drug Administration (FDA) quality and safety standards. (7)Provide evidence of Verified Accredited Wholesale Distributors (VAWD) certification. (8)Facility to be FDA and current Good Manufacturing Practices (cGMP) compliant.. (9)Provide past performance of providing required product. (10)Capability for ground shipping, three (3) to five (5) days, backorders being delivered within two (2) weeks. 6.0Questions Questions regarding this announcement shall be submitted in writing by e-mail to the Contracting Officer, ldgillman@fbi.gov no later than June 27, 2018, 1:00PM EST. Verbal questions will NOT be accepted. Questions will be answered by posting answers to the FedBizOpps website; accordingly, questions shall NOT contain proprietary or classified information. The Government does not guarantee that questions received after June 27, 2018, 1:00PM EST will be answered. 7.0Summary THIS IS A REQUEST FOR INFORMATION (RFI) ONLY to identify sources that can provide an Enterprise Wide Office Supply system. The information provided in the RFI is subject to change and is not binding on the Government. The FBI has not made a commitment to procure any of the items discussed, and release of this RFI, to include all attachments, should not be construed as such a commitment or as authorization to incur cost for which reimbursement would be required or sought. All submissions become Government property and will not be returned.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DOJ/FBI/PPMS1/RFI-HCPU-18-317/listing.html)
- Place of Performance
- Address: Federal Bureau of Investigation, STAU - Science and Technology Acquisition Unit, 935 Pennsylvania Avenue, NW, Washington, DC 20535-0001, Washington, District of Columbia, 20535-0001, United States
- Zip Code: 20535-0001
- Zip Code: 20535-0001
- Record
- SN04969261-W 20180628/180626231124-cd6d9c3fc2e3c4e5fdf57b56bd669956 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |